NRG
EIGR

Nemes Rush Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Nemes Rush Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27
Closed -$569 – 732
2023
Q2 		$569 Buy
+27
New +$832 ﹤0.01% 636

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nemes Rush Group's EIGR Position: Q3 2023 in Review

Nemes Rush Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 27 shares — an estimated $569 sold.

Nemes Rush Group first reported a position in EIGR in Q2 2023 and held it in 1 quarter. The position peaked at $569 in Q2 2023. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Nemes Rush Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Nemes Rush Group sold 27 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $569.
  • Nemes Rush Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
  • Nemes Rush Group's Eiger BioPharmaceuticals, Inc. position peaked at $569 in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Nemes Rush Group's 13F filing for Q3 2023, filed 9 Nov 2023.